Raywjj92 personal page - To The Moon

Raywjj92

Raywjj92

No personal profile

27Follow

1Followers

0Topic

0Badge

2024-10-29

$DiDi Global Inc.(DIDIY)$

2021-05-02

Time to play the game

3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners

2021-05-02

Nice detailed article

Sorry, the original content has been removed

2021-05-01

Good opportunity?

3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street

2021-05-01

$Qualcomm(QCOM)$Come on Qualcomm

2021-04-28

Nice article

5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street

2021-02-12

Great article

Here's the formula for spotting genuinely undervalued companies, claims this investment house

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3575030447100890","uuid":"3575030447100890","gmtCreate":1611936560419,"gmtModify":1619620831004,"name":"Raywjj92","pinyin":"raywjj92","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":27,"tweetSize":7,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.03.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.06.07","exceedPercentage":"60.07%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":8,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":365191440302136,"gmtCreate":1730168404936,"gmtModify":1730168406847,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$DiDi Global Inc.(DIDIY)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365191440302136","isVote":1,"tweetType":1,"viewCount":556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101497940,"gmtCreate":1619928874980,"gmtModify":1704336493523,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"Time to play the game&nbsp;","listText":"Time to play the game&nbsp;","text":"Time to play the game","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101497940","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://ttm.financial/m/news/1115363330?lang=en_US&edition=fundamental","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101496942,"gmtCreate":1619928614186,"gmtModify":1704336488131,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"Nice detailed&nbsp;article","listText":"Nice detailed&nbsp;article","text":"Nice detailed article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101496942","repostId":"1103106179","repostType":4,"isVote":1,"tweetType":1,"viewCount":882,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103773825,"gmtCreate":1619827498567,"gmtModify":1704335361878,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"Good opportunity?&nbsp;","listText":"Good opportunity?&nbsp;","text":"Good opportunity?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/103773825","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","kind":"news","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=en_US&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3567411499210880","authorId":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3567411499210880","idStr":"3567411499210880"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103745740,"gmtCreate":1619827235180,"gmtModify":1704335355026,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","listText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","text":"$Qualcomm(QCOM)$Come on Qualcomm","images":[{"img":"https://static.tigerbbs.com/ed08922766e5a885016453299394bd3a","width":"750","height":"1300"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/103745740","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":100278931,"gmtCreate":1619619175923,"gmtModify":1704726925624,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"Nice article","listText":"Nice article","text":"Nice article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/100278931","repostId":"1138128459","repostType":4,"repost":{"id":"1138128459","kind":"news","pubTimestamp":1619608043,"share":"https://ttm.financial/m/news/1138128459?lang=en_US&edition=fundamental","pubTime":"2021-04-28 19:07","market":"us","language":"en","title":"5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1138128459","media":"Motley Fool","summary":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on M","content":"<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-based<b>S&amp;P 500</b>has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.</p>\n<p>Yet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Shopify: Implied upside of 31%</p>\n<p>First up is my absolute favorite software-as-a-service (SaaS) stock,<b>Shopify</b>(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.</p>\n<p>Shopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.</p>\n<p>What's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes of<b>Walmart</b>&nbsp;and<b>Pinterest</b>to streamline aspects of their online sales platforms.</p>\n<p>Shopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.</p>\n<p><img src=\"https://static.tigerbbs.com/df219df7b01fbc2aa008c455f28b99e5\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Teladoc Health: Implied upside of 40%</p>\n<p>Telemedicine giant<b>Teladoc Health</b>(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.</p>\n<p>As you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.</p>\n<p>But understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.</p>\n<p>Furthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.</p>\n<p><img src=\"https://static.tigerbbs.com/0e47e6b6eced3a10e200ffd777619a0c\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Snowflake: Implied upside of 28%</p>\n<p>Another high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing company<b>Snowflake</b>(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.</p>\n<p>As I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.</p>\n<p>Arguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.</p>\n<p>Even better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.</p>\n<p>Snowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.</p>\n<p><img src=\"https://static.tigerbbs.com/bbafad9e87b7b7dacfefe92d4741b655\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Datadog: Implied upside of 35%</p>\n<p>Have I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions provider<b>Datadog</b>(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.</p>\n<p>Keeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.</p>\n<p>What's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.</p>\n<p>Similar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.</p>\n<p><img src=\"https://static.tigerbbs.com/99b3853458b2424e2901821012f5502f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Coinbase: Implied upside of 56%</p>\n<p>Finally, recent initial public offering<b>Coinbase</b>(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.</p>\n<p>There's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies like<b>Bitcoin</b>and&nbsp;<b>Ethereum</b>. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!</p>\n<p>However, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.</p>\n<p>Furthermore,its business model looks to be built upon euphoria&nbsp;rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.</p>\n<p>In sum, Wall Street may be bullish on Coinbase, but this Fool isn't.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","COIN":"Coinbase Global, Inc.","SHOP":"Shopify Inc","SNOW":"Snowflake","DDOG":"Datadog"},"source_url":"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138128459","content_text":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.\nYet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.\n\nIMAGE SOURCE: GETTY IMAGES.\nShopify: Implied upside of 31%\nFirst up is my absolute favorite software-as-a-service (SaaS) stock,Shopify(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.\nShopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.\nWhat's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes ofWalmart andPinterestto streamline aspects of their online sales platforms.\nShopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.\n\nIMAGE SOURCE: GETTY IMAGES.\nTeladoc Health: Implied upside of 40%\nTelemedicine giantTeladoc Health(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.\nAs you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.\nBut understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.\nFurthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.\n\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: Implied upside of 28%\nAnother high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing companySnowflake(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.\nAs I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.\nArguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.\nEven better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.\nSnowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.\n\nIMAGE SOURCE: GETTY IMAGES.\nDatadog: Implied upside of 35%\nHave I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions providerDatadog(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.\nKeeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.\nWhat's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.\nSimilar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.\n\nIMAGE SOURCE: GETTY IMAGES.\nCoinbase: Implied upside of 56%\nFinally, recent initial public offeringCoinbase(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.\nThere's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies likeBitcoinand Ethereum. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!\nHowever, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.\nFurthermore,its business model looks to be built upon euphoria rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.\nIn sum, Wall Street may be bullish on Coinbase, but this Fool isn't.","news_type":1,"symbols_score_info":{"SHOP":0.9,"TDOC":0.9,"DDOG":0.9,"SNOW":0.9,"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386924555,"gmtCreate":1613128927477,"gmtModify":1704878675671,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3575030447100890","idStr":"3575030447100890"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386924555","repostId":"2110026963","repostType":4,"repost":{"id":"2110026963","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613109422,"share":"https://ttm.financial/m/news/2110026963?lang=en_US&edition=fundamental","pubTime":"2021-02-12 13:57","market":"us","language":"en","title":"Here's the formula for spotting genuinely undervalued companies, claims this investment house","url":"https://stock-news.laohu8.com/highlight/detail?id=2110026963","media":"Dow Jones","summary":"The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis. For most of 2020, investors poured money into names like online retailer Amazon $$, electric-car maker Tesla $$, and e-commerce platform Shopify -- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.But when news broke in early November 2020 that drug company Pfizer $$ and its partner BioNTech $$ had developed an effective vaccine against COVID-19, something pro","content":"<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's the formula for spotting genuinely undervalued companies, claims this investment house</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's the formula for spotting genuinely undervalued companies, claims this investment house\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-12 13:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","relate_stocks":{"PFE":"辉瑞","AMZN":"亚马逊","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2110026963","content_text":"MW Here's the formula for spotting genuinely undervalued companies, claims this investment house\nThe growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis\nFor most of 2020, investors poured money into names like online retailer Amazon $(AMZN)$, electric-car maker Tesla $(TSLA)$, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.\nBut when news broke in early November 2020 that drug company Pfizer $(PFE)$ and its partner BioNTech $(BNTX)$ had developed an effective vaccine against COVID-19, something profound happened in financial markets.\nInvestors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.\nThis rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.\nAnd it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.\nThe apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.\n\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.\n\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"\nAnalysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.\nThe value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.\nIn reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.\nStocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.\nTo have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.","news_type":1,"symbols_score_info":{"AMZN":0.9,"TSLA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":103773825,"gmtCreate":1619827498567,"gmtModify":1704335361878,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Good opportunity?&nbsp;","listText":"Good opportunity?&nbsp;","text":"Good opportunity?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/103773825","repostId":"1165708828","repostType":4,"repost":{"id":"1165708828","kind":"news","pubTimestamp":1619792862,"share":"https://ttm.financial/m/news/1165708828?lang=en_US&edition=fundamental","pubTime":"2021-04-30 22:27","market":"us","language":"en","title":"3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1165708828","media":"Motley Fool","summary":"For more than a year, patient investors have been handsomely rewarded. All three of the market's maj","content":"<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.</p>\n<p>Yet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in the<b>S&amp;P 500</b>,<b>Dow Jones Industrial Average</b>, and<b>Nasdaq Composite</b>, this represents a huge underperformance.</p>\n<p>But according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.</p>\n<p>Sarepta Therapeutics: Implied upside of 91%</p>\n<p>Many of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developer<b>Sarepta Therapeutics</b>(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.</p>\n<p>Sarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.</p>\n<p>However, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.&nbsp; In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.</p>\n<p>The Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.</p>\n<p>Intercept Pharmaceuticals: Implied upside of 97%</p>\n<p>If you wanteven more upside potential, Wall Street would steer you toward small-cap<b>Intercept Pharmaceuticals</b>(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.</p>\n<p>Similar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.</p>\n<p>Intercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.</p>\n<p>On the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.</p>\n<p>If OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.</p>\n<p>It's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.</p>\n<p>Inovio Pharmaceuticals: Implied upside of 104%</p>\n<p>Yet another biotech stock withbig-time upside potential, according to Wall Street, is<b>Inovio Pharmaceuticals</b>(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.</p>\n<p>For much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.</p>\n<p>Unfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.</p>\n<p>There are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players like<b>Johnson &amp; Johnson</b>&nbsp;can produce up to 3 billion doses for the global market this year. As a reminder, J&amp;J's vaccine is a single-dose treatment.</p>\n<p>The other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.</p>\n<p>With a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Turnaround Stocks With 91% to 104% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-turnaround-stocks-91-to-104-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165708828","content_text":"For more than a year, patient investors have been handsomely rewarded. All three of the market's major indexes have gained between 83% and 106% since hitting the bear-market bottom set on March 23, 2020.\nYet, not all stocks have participated in the rally. Over the trailing year (through April 27, 2021), around 110 stocks with at least a $300 million market cap have declined by 20% (or more). Given the aforementioned big gains in theS&P 500,Dow Jones Industrial Average, andNasdaq Composite, this represents a huge underperformance.\nBut according to analysts on Wall Street, some of these underperformers have a good chance to bounce back in a big way over the coming year. Based on consensus one-year price targets, the following three turnaround stocks offer upside ranging from 91% to as much as 104%.\nSarepta Therapeutics: Implied upside of 91%\nMany of the worst-performing equities over the past year arebiotech stocks. With investors rolling the dice on future clinical outcomes, trial data announcements can yield wild price swings for drug developers. Shareholders of specialized drug developerSarepta Therapeutics(NASDAQ:SRPT)learned this in January when shares of the company were halved in a day. But if Wall Street's one-year price target is correct, Sarepta could recoup most of its losses by gaining 91% from its April 27 close.\nSarepta's bread and butter is its research in treating Duchenne Muscular Dystrophy (DMD). DMD is an incurable disease diagnosed in children that leads to the destruction of muscle and causes premature death. To date, the company has had the U.S. Food and Drug Administration (FDA) approve three of its gene-specific DMD treatments, which are designed to increase the production of dystrophin.\nHowever, themake-or-break treatmentin the company's pipeline is SRP-9001. This is an experimental treatment that utilizes an adeno-associated virus to deliver a gene to muscle tissue that \"programs\" for micro-dystrophin production.  In other words, SRP-9001 would allow the company to treat a much larger percentage of DMD patients.\nThe Part 1 data release of Study 102 evaluating SRP-9001 in DMD patients aged 4 to 7 is why the stock was halved in January. Although treated participants showed an increase in their North Star Ambulatory Assessment (NSAA) total score,it wasn't statistically significant. Sarepta, however, blamed this disappointment on fitness differences in its patients during the study and expects a much different outcome in the latter half of this study. Part 2 of Study 102 is, therefore, Sarepta's make-or-break DMD moment.\nIntercept Pharmaceuticals: Implied upside of 97%\nIf you wanteven more upside potential, Wall Street would steer you toward small-capIntercept Pharmaceuticals(NASDAQ:ICPT). Among the 4,000-plus securities with at least a $300 million market cap, it holds the distinction of being the absolute worst performer over the trailing year (down 75%). The only solace is that Wall Street's consensus price target would see Intercept gain 97% over the coming year.\nSimilar to Sarepta, Intercept's future predominantly lies with one indication: nonalcoholic steatohepatitis, or NASH. NASH is a liver disease that affects between 2% and 5% of the U.S. adult population and has no FDA-approved cure. It can lead to fibrosis, liver cancer, and even death. It's been estimated that NASH represents a $35 billion treatment opportunity.\nIntercept is at the forefront of that opportunity, but it's not been without its hiccups. Experimental treatment obeticholic acid (OCA)met one of its two co-primary endpointsin the phase 3 Regenerate study -- a statistically significant reduction in liver fibrosis without a worsening in NASH. Only one met endpoint was needed to declare the trial a success.\nOn the other hand, the highest dose (also the most effective) led to considerably higher instances of pruritus (itching) and trial discontinuation, relative to the placebo. Perhaps unsurprisingly, Interceptreceived a Complete Response Letterfrom the FDA following its new drug application to supply additional safety data.\nIf OCA were to be approved, even for a small subset of the sickest patients, it would represent a greater than $1 billion sales opportunity.\nIt's also worth noting that OCA is already approved under the brand name Ocaliva as a treatment for primary biliary cholangitis (PBC). With Ocaliva's PBC sales expected to hit at least $325 million in 2021 (nearly half the company's market cap), investors look to begetting a shot at NASH success nearly for free.\nInovio Pharmaceuticals: Implied upside of 104%\nYet another biotech stock withbig-time upside potential, according to Wall Street, isInovio Pharmaceuticals(NASDAQ:INO). Shares of the company have been clobbered recently, but are expected to rally by 104% to nearly $15 based on the consensus 12-month price target of analysts.\nFor much of the past year, the promise and peril of Inovio have rested with its development of a coronavirus disease 2019 (COVID-19) vaccine. The company's candidate, INO-4800, achieved immunological responses in 38 of 38 patients in phase 1 studies and looked to be on track to be among the roughly six or so early contenders to bring a COVID-19 vaccine to market in the United States.\nUnfortunately, Inovio's phase 2 and 3 studies hit a snag. The FDA placed a partial clinical hold on both phases and requested additional information concerning INO-4800 and the company's Cellectra delivery device. Cellectra uses electrical impulses to open pores in cells to allow plasmids to enter. Though the partial hold on the phase 2 study was lifted, the company has yet to run an all-important phase 3 study and may choose to do so outside the United States. To top things off, the U.S. Department of Defense notified Inovio that it wouldno longer be providing funding for its phase 3 study.\nThere are two very big problems here. First, Inovio is running out of time to become a major player in treating COVID-19. The U.S. vaccination campaign will likely be complete sometime in July, and major players likeJohnson & Johnson can produce up to 3 billion doses for the global market this year. As a reminder, J&J's vaccine is a single-dose treatment.\nThe other potential red flag isInovio's track record. The company may have an intriguing delivery device in Cellectra, as well as nearly a dozen unique compounds in clinical trials, but it's yet to have the FDA approve any of its experimental treatments in four decades.\nWith a number of its studies partnered, it's always possible Inovio could turn itself around. But given its track record, it may be best off avoided.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":698,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3567411499210880","authorId":"3567411499210880","name":"Nebhol","avatar":"https://static.tigerbbs.com/b0bfc2a45b91e41a283614268857b3a5","crmLevel":11,"crmLevelSwitch":0,"idStr":"3567411499210880","authorIdStr":"3567411499210880"},"content":"Like and comment","text":"Like and comment","html":"Like and comment"}],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101497940,"gmtCreate":1619928874980,"gmtModify":1704336493523,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Time to play the game&nbsp;","listText":"Time to play the game&nbsp;","text":"Time to play the game","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101497940","repostId":"1115363330","repostType":4,"repost":{"id":"1115363330","kind":"news","pubTimestamp":1619791216,"share":"https://ttm.financial/m/news/1115363330?lang=en_US&edition=fundamental","pubTime":"2021-04-30 22:00","market":"us","language":"en","title":"3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners","url":"https://stock-news.laohu8.com/highlight/detail?id=1115363330","media":"Motley Fool","summary":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly righ","content":"<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't win<i>all</i>of the time. They have their ups and downs.</p>\n<p>Case in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.</p>\n<p>Several of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.</p>\n<p>Teladoc Health</p>\n<p><b>Teladoc Health</b>(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in the<b>ARK Genomic Revolution ETF</b>, the second-largest position in the<b>ARK Innovation ETF</b>, and the fifth-largest holding in the<b>ARK Next Generation Internet ETF</b>.</p>\n<p>It appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.</p>\n<p>However, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.</p>\n<p>My view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.</p>\n<p>Unity Software</p>\n<p><b>Unity Software</b>(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.</p>\n<p>The main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.</p>\n<p>I don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust to<b>Apple</b>'s new IDFA user identification method.</p>\n<p>Unity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.</p>\n<p>Vertex Pharmaceuticals</p>\n<p><b>Vertex Pharmaceuticals</b>(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.</p>\n<p>Wall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.</p>\n<p>However, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.</p>\n<p>I fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 of Cathie Wood's Biggest Losers of 2021 That Should Still Be Huge Long-Term Winners\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-30 22:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/04/30/3-of-cathie-woods-biggest-losers-of-2021-that-shou/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1115363330","content_text":"David Gardner, a co-founder of The Motley Fool, often says that \"winners win.\" And he's exactly right. However, he would be the first to tell you that winners don't winallof the time. They have their ups and downs.\nCase in point: Cathie Wood certainly qualifies as a winner. Her ARK Invest exchange-traded funds have ranked among the best-performing ETFs in recent years. Not every stock in those funds has delivered a great return so far in 2021, though.\nSeveral of the ARK Invest CEO's favorites are actually down year to date. Don't count all of those recent underperformers out just yet, though. These three are among Wood's biggest losers of 2021, and all should still be huge winners over the long run.\nTeladoc Health\nTeladoc Health(NYSE:TDOC)shares have fallen more than 15% year to date, and that's weighing on several of Wood's ETFs. Teladoc is the top holding in theARK Genomic Revolution ETF, the second-largest position in theARK Innovation ETF, and the fifth-largest holding in theARK Next Generation Internet ETF.\nIt appears that many investors are focusing only on the negatives for Teladoc. For example,in its Q1 update, the company reported a huge net loss and said that U.S. paid membership in the quarter slipped to 51.5 million from 51.8 million in the fourth quarter of 2020.\nHowever, that's only part of the story. Teladoc's total visits and utilization rate continue to climb. And much of that big loss was related to the company's acquisitions of Livongo and InTouch Health, deals that are already helping drive its revenue growth.\nMy view is that Teladoc's downturn will be temporary. The long-term opportunities for the company in virtual care remain exceptionally strong.\nUnity Software\nUnity Software(NYSE:U)has been an especially poor performer for Wood this year -- the stock has plunged more than 30%. The gaming platform leader ranks No. 10 among the ARK Next Generation Internet ETF's holdings and No. 12 for the ARK Innovation ETF.\nThe main knock against Unity is its slowing growth rate. In the fourth quarter of 2020, the company reported a 39% year-over-year revenue increase. However, that was weaker than its full-year revenue growth rate of 43%. Even more concerning, Unity provided a full-year revenue guidance range for 2021 anticipating growth of 24% at the midpoint.\nI don't think investors should be worried, though. For one thing, the pandemic boosted Unity's growth in 2020. It's not surprising that growth would slow somewhat after such an exceptional year. The company also anticipates taking a one-time hit to revenue in 2021 as advertisers adjust toApple's new IDFA user identification method.\nUnity still expects to generate annual revenue growth of at least 30% over the long term. Wood clearly remains a fan of the stock -- her ARK Innovation ETFscooped up more sharesrecently. I think that her optimism in this case is spot on.\nVertex Pharmaceuticals\nVertex Pharmaceuticals(NASDAQ:VRTX)hasn't been quite as big of a problem for Wood in 2021 as Teladoc and Unity. However, thebiotech stockhas fallen more than 10% year to date. It's the seventh-largest position for the ARK Genomic Revolution ETF.\nWall Street analysts weren't happy with the Q4 results Vertex reported in February. Although the company narrowly beat revenue expectations, its adjusted earnings came in below analysts' estimates. Vertex also provided guidance for 2021 that anticipated slowing growth.\nHowever, Vertex still has a big market opportunity ahead for its newest cystic fibrosis treatment, Trikafta/Kaftrio, in Europe. The triple-drug combination quickly became a blockbuster in the U.S. after winning approval. However, its growth curve in Europe will take more time because Vertex has to negotiate reimbursement deals with the healthcare regulators in each individual country.\nI fully expect Vertex will achieve tremendous success outside of the cystic fibrosis market over the next few years. The big biotech seems really confident about the prospects for its candidate gene-editing therapy CTX001 in treating a pair of rare blood disorders: sickle cell disease and beta-thalassemia. It also has other promising pipeline candidates as well as a hefty cash stockpile. Vertex, like Teladoc and Unity, looks like a long-term winner despite its losing ways of late.","news_type":1,"symbols_score_info":{}},"isVote":1,"tweetType":1,"viewCount":844,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":101496942,"gmtCreate":1619928614186,"gmtModify":1704336488131,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Nice detailed&nbsp;article","listText":"Nice detailed&nbsp;article","text":"Nice detailed article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/101496942","repostId":"1103106179","repostType":4,"isVote":1,"tweetType":1,"viewCount":882,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":103745740,"gmtCreate":1619827235180,"gmtModify":1704335355026,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","listText":"<a href=\"https://laohu8.com/S/QCOM\">$Qualcomm(QCOM)$</a>Come on Qualcomm","text":"$Qualcomm(QCOM)$Come on Qualcomm","images":[{"img":"https://static.tigerbbs.com/ed08922766e5a885016453299394bd3a","width":"750","height":"1300"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/103745740","isVote":1,"tweetType":1,"viewCount":631,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":365191440302136,"gmtCreate":1730168404936,"gmtModify":1730168406847,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","listText":"<a href=\"https://ttm.financial/S/DIDIY\">$DiDi Global Inc.(DIDIY)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;","text":"$DiDi Global Inc.(DIDIY)$","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/365191440302136","isVote":1,"tweetType":1,"viewCount":556,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":100278931,"gmtCreate":1619619175923,"gmtModify":1704726925624,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Nice article","listText":"Nice article","text":"Nice article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/100278931","repostId":"1138128459","repostType":4,"repost":{"id":"1138128459","kind":"news","pubTimestamp":1619608043,"share":"https://ttm.financial/m/news/1138128459?lang=en_US&edition=fundamental","pubTime":"2021-04-28 19:07","market":"us","language":"en","title":"5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=1138128459","media":"Motley Fool","summary":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on M","content":"<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-based<b>S&amp;P 500</b>has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.</p>\n<p>Yet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.</p>\n<p><img src=\"https://static.tigerbbs.com/d19c9dd5972bb303415e3fb9e20fb2d4\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Shopify: Implied upside of 31%</p>\n<p>First up is my absolute favorite software-as-a-service (SaaS) stock,<b>Shopify</b>(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.</p>\n<p>Shopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.</p>\n<p>What's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes of<b>Walmart</b>&nbsp;and<b>Pinterest</b>to streamline aspects of their online sales platforms.</p>\n<p>Shopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.</p>\n<p><img src=\"https://static.tigerbbs.com/df219df7b01fbc2aa008c455f28b99e5\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Teladoc Health: Implied upside of 40%</p>\n<p>Telemedicine giant<b>Teladoc Health</b>(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.</p>\n<p>As you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.</p>\n<p>But understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.</p>\n<p>Furthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.</p>\n<p><img src=\"https://static.tigerbbs.com/0e47e6b6eced3a10e200ffd777619a0c\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Snowflake: Implied upside of 28%</p>\n<p>Another high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing company<b>Snowflake</b>(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.</p>\n<p>As I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.</p>\n<p>Arguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.</p>\n<p>Even better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.</p>\n<p>Snowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.</p>\n<p><img src=\"https://static.tigerbbs.com/bbafad9e87b7b7dacfefe92d4741b655\" tg-width=\"700\" tg-height=\"393\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Datadog: Implied upside of 35%</p>\n<p>Have I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions provider<b>Datadog</b>(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.</p>\n<p>Keeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.</p>\n<p>What's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.</p>\n<p>Similar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.</p>\n<p><img src=\"https://static.tigerbbs.com/99b3853458b2424e2901821012f5502f\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"></p>\n<p>IMAGE SOURCE: GETTY IMAGES.</p>\n<p>Coinbase: Implied upside of 56%</p>\n<p>Finally, recent initial public offering<b>Coinbase</b>(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.</p>\n<p>There's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies like<b>Bitcoin</b>and&nbsp;<b>Ethereum</b>. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!</p>\n<p>However, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.</p>\n<p>Furthermore,its business model looks to be built upon euphoria&nbsp;rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.</p>\n<p>In sum, Wall Street may be bullish on Coinbase, but this Fool isn't.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Ultra-Popular Growth Stocks With 28% to 56% Upside, According to Wall Street\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-28 19:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TDOC":"Teladoc Health Inc.","COIN":"Coinbase Global, Inc.","SHOP":"Shopify Inc","SNOW":"Snowflake","DDOG":"Datadog"},"source_url":"https://www.fool.com/investing/2021/04/28/5-growth-stocks-with-28-to-56-upside-wall-street/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138128459","content_text":"For 13 months, Wall Street has proved virtually unstoppable. Since hitting a bear market bottom on March 23, 2020, the broad-basedS&P 500has galloped higher by 87%, through this past weekend. This handily outpaces the average bounce-back rally from a bear-market bottom and leaves the historic average annual return for the benchmark index eating dust.\nYet even at these lofty levels, Wall Street professionals see value. Based on the consensus one-year price targets of Wall Street analysts, five of the most populargrowth stocksoffer implied upside ranging from a low of 28% to as much as 56%.\n\nIMAGE SOURCE: GETTY IMAGES.\nShopify: Implied upside of 31%\nFirst up is my absolute favorite software-as-a-service (SaaS) stock,Shopify(NYSE:SHOP). Even after gaining more than 1,000% over the past 3.5 years, Wall Street believes the company's stock offers an additional 31% upside to $1,434 a share over the next year.\nShopify's operating model of providing cloud-based e-commerce solutions to (primarily) small businessescouldn't be in a better place at the moment. Although it was initially hit by the pandemic with virtually all other retail-oriented companies, it quickly became apparent that Shopify's e-commerce platform would be a logical beneficiary as businesses shifted course and pushed online. The result was a 96% increase in gross merchandise value (GMV) transacted across its platform in 2020 to $119.6 billion. Over the past six years, GMV has grown at a compound annual rate of 77.7%.\nWhat's made Shopify tick is both the discovery of the platform by new merchants and the ability to snag worthwhile deals with major retailers. The number of consumers using the platform increased by approximately 52% last year to 457 million. Meanwhile, itpartneredwith the likes ofWalmart andPinterestto streamline aspects of their online sales platforms.\nShopify isn't remotely inexpensive on a fundamental basis. But if it can continue to grow its GMV at these insane levels, investors will gladly pay a hefty premium to own Shopify stock.\n\nIMAGE SOURCE: GETTY IMAGES.\nTeladoc Health: Implied upside of 40%\nTelemedicine giantTeladoc Health(NYSE:TDOC)has been exceptionally popular over the past year, for obvious reasons I'll touch on in a moment. According to Wall Street, shares of Teladoc could ascend past $250 over the next 12 months, giving it an implied upside of 40%.\nAs you can imagine, physicians wanted to keep at-risk people and potentially infected patients out of offices and hospitals if at all possible last year. This led to Teladoc handling almost 10.6 million virtual visits in 2020, up from around 4.1 million in the previous year.\nBut understand that telehealth is agame-changing healthcare modeland not just a one-year wonder because of the pandemic. It's far more convenient for patients, allows physicians to keep closer tabs on at-risk patients, and is usually billed at a lower rate than office visits, which health insurers love. These advantages are exactly why Teladoc's sales grew by an average annual rate of 74% between 2013 and 2019.\nFurthermore, Teladoc has a new toy, so to speak: Itacquired leading applied health signals company Livongo Healthin early November. Livongo leans on artificial intelligence to send tips and nudges to patients with chronic illnesses. These nudges help patients make behavioral changes that result in their leading healthier lives. The addition of Livongo makes Teladoc a veritable no-brainer buy.\n\nIMAGE SOURCE: GETTY IMAGES.\nSnowflake: Implied upside of 28%\nAnother high-growth stock with abundant upside according to Wall Street professionals is cloud data warehousing companySnowflake(NYSE:SNOW). After recently retracing to an all-time low, analysts see Snowflake gaining up to 28% to almost $301 a share over the next 12 months.\nAs I alluded to with Shopify, we're witnessing a big push by businesses online and into the cloud, which has been a boon for most cloud infrastructure companies. Despite the worst economic downturn in decades, Snowflake grew its product revenue by 120% to $553.8 million in fiscal 2021. Although it's losing a lot of money at the moment, the services Snowflake offers should yield juicy margins as the company matures.\nArguably the most interesting thing about Snowflake is itssustainable competitive advantages. For instance, it offers a pay-as-you-go model that shuns the subscriptions that SaaS stocks often covet. By allowing its customers to pay based on their storage needs and Snowflake Compute Credits used, it's offering a highly transparent and cost-effective operating model.\nEven better, its platform islayered atop the most popular cloud infrastructure solutions, which makes the sharing of information seamless, regardless of storage provider.\nSnowflake has some very big shoes to fill with its lofty valuation, but Wall Street believes the company can get it done.\n\nIMAGE SOURCE: GETTY IMAGES.\nDatadog: Implied upside of 35%\nHave I mentioned that Wall Street has a thing forSaaS stocks? In addition to Shopify and Snowflake, analysts believe that application monitoring solutions providerDatadog(NASDAQ:DDOG)could surge to $121 a share over the next year. This implies up to 35% upside in its shares.\nKeeping with the theme, Datadog looks to benefit from businesses completely shifting their strategy in the wake of the pandemic. With employees working remotely, it's become more important than ever that businesses stay on top of key metrics, oversee critical applications, and fully understand the behavior of their customers. Datadog's cloud-based solutions do all of this for its clients.\nWhat's been most impressive about Datadog is the company's ability to attract bigger clients. While a 46% increase in customers with at least $100,000 in annual recurring revenue (ARR) is nice, the \"wow\" number is the 94% increase in the number of customers generating at least $1 million in ARR. This is a big reason the company's sales shot 66% higher in 2020 to $603.5 million.\nSimilar to Snowflake, Datadog has a lot to prove with its lofty price-to-sales ratio. However, if it can continue to grow its sales by more than 30% annually, there'sno reason Wall Street's price target isn't within reach.\n\nIMAGE SOURCE: GETTY IMAGES.\nCoinbase: Implied upside of 56%\nFinally, recent initial public offeringCoinbase(NASDAQ:COIN)offers the highest perceived upside among these five fast-growing companies. Though there were only four price targets listed through this past weekend, a lofty target of $600 a share skewed the consensus up to $456 a share. This suggests Coinbase could gain 56% over the coming 12 months.\nThere's no doubt that Coinbase has benefited from the euphoria surrounding cryptocurrencies likeBitcoinand Ethereum. With both rallying to new highs this year, Coinbase recorded $1.8 billion in revenue in the first quarter. For some context, that's more revenue than it had generated in the previous 24 months combined!\nHowever, unlike the other popular companies listed here,Coinbase's advantages look flimsy, at best. It runs the risk of competing crypto brokerages undercutting its fees, which could reduce its operating margins and growth rate dramatically over time.\nFurthermore,its business model looks to be built upon euphoria rather than innovation. With most of its revenue coming from Bitcoin and Ethereum trading, it's worrisome to see what happens when the price of these key assets stops rising. In a two-year stretch where Bitcoin lost 80% of its value, Coinbase saw its revenue nearly get halved.\nIn sum, Wall Street may be bullish on Coinbase, but this Fool isn't.","news_type":1,"symbols_score_info":{"SHOP":0.9,"TDOC":0.9,"DDOG":0.9,"SNOW":0.9,"COIN":0.9}},"isVote":1,"tweetType":1,"viewCount":717,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":386924555,"gmtCreate":1613128927477,"gmtModify":1704878675671,"author":{"id":"3575030447100890","authorId":"3575030447100890","name":"Raywjj92","avatar":"https://static.tigerbbs.com/57550c84d835f65dcf57fd3bf7c5d66b","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3575030447100890","authorIdStr":"3575030447100890"},"themes":[],"htmlText":"Great article","listText":"Great article","text":"Great article","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/386924555","repostId":"2110026963","repostType":4,"repost":{"id":"2110026963","kind":"highlight","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1613109422,"share":"https://ttm.financial/m/news/2110026963?lang=en_US&edition=fundamental","pubTime":"2021-02-12 13:57","market":"us","language":"en","title":"Here's the formula for spotting genuinely undervalued companies, claims this investment house","url":"https://stock-news.laohu8.com/highlight/detail?id=2110026963","media":"Dow Jones","summary":"The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis. For most of 2020, investors poured money into names like online retailer Amazon $$, electric-car maker Tesla $$, and e-commerce platform Shopify -- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.But when news broke in early November 2020 that drug company Pfizer $$ and its partner BioNTech $$ had developed an effective vaccine against COVID-19, something pro","content":"<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Here's the formula for spotting genuinely undervalued companies, claims this investment house</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHere's the formula for spotting genuinely undervalued companies, claims this investment house\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-02-12 13:57</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>MW Here's the formula for spotting genuinely undervalued companies, claims this investment house</p>\n<p>The growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis</p>\n<p>For most of 2020, investors poured money into names like online retailer Amazon <a href=\"https://laohu8.com/S/AMZN\">$(AMZN)$</a>, electric-car maker Tesla <a href=\"https://laohu8.com/S/TSLA\">$(TSLA)$</a>, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.</p>\n<p>But when news broke in early November 2020 that drug company Pfizer <a href=\"https://laohu8.com/S/PFE\">$(PFE)$</a> and its partner BioNTech <a href=\"https://laohu8.com/S/BNTX\">$(BNTX)$</a> had developed an effective vaccine against COVID-19, something profound happened in financial markets.</p>\n<p>Investors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.</p>\n<p>This rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.</p>\n<p>And it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.</p>\n<p>The apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.</p>\n<p>\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.</p>\n<p>\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"</p>\n<p>Analysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.</p>\n<p>The value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.</p>\n<p>In reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.</p>\n<p>Stocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.</p>\n<p>To have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/15e20574f8fb568333181d61bb200086","relate_stocks":{"PFE":"辉瑞","AMZN":"亚马逊","TSLA":"特斯拉"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2110026963","content_text":"MW Here's the formula for spotting genuinely undervalued companies, claims this investment house\nThe growth stock vs. value stock dichotomy doesn't make sense, says ValuAnalysis\nFor most of 2020, investors poured money into names like online retailer Amazon $(AMZN)$, electric-car maker Tesla $(TSLA)$, and e-commerce platform Shopify (SHOP.T)-- \"growth\" stocks that kept indexes afloat in a turbulent year that hammered share prices across the board.\nBut when news broke in early November 2020 that drug company Pfizer $(PFE)$ and its partner BioNTech $(BNTX)$ had developed an effective vaccine against COVID-19, something profound happened in financial markets.\nInvestors rotated out of these investments in favor of \"value\" stocks hammered by the COVID-19 pandemic, like airlines.\nThis rotation was based on an essential concept in investing: There are some stocks that are clearly undervalued based on standard metrics.\nAnd it is completely flawed, according to research from ValuAnalysis, a London-based fund manager and equity investment boutique, which specializes in valuation.\nThe apparent difference between growth stocks and value stocks is that the former is overvalued based on fundamental metrics while the latter is undervalued.\n\"Everyone knows that this thing doesn't make any sense because growth is not the opposite of value,\" Pascal Costantini, who led the research at ValuAnalysis, tells MarketWatch.\n\"It should be high-growth and low-growth, and I can imagine that, somewhere in an office, some guy said 'well this is not catchy enough, so how about growth and value?'\"\nAnalysts and investors use metrics like the price-to-earnings ratio, or price multiple, to value stocks. ValuAnalysis uses price as a multiple of normalized net free cash flow as its benchmark, and identifies the imaginary dividing line between value and growth stocks at 35x, which is the market median.\nThe value vs. growth divide would suggest that a company trading at a 17x earnings multiple is undervalued. In reality, ValuAnalysis says it is likely a company that won't grow.\nIn reality, a stock's value is based on the company's ability to grow free cash flow in an environment where the cost of capital is 5% to 6%. So if a company isn't outpacing that by improving revenue and margins, the multiple won't increase and the stock price is unlikely to rise.\nStocks that are actually undervalued will trade between 25x and 35x free cash flow, Costantini says, outpacing the cost of capital but not breaking past the market median.\nTo have potential, a company's accumulation of assets or revenue growth must outpace increases in global gross domestic product, and ideally show signs of accelerating. There must also be an increase in operational leverage through revenue or margins. A decrease in the risk premium, such as through advances in controlling carbon emissions, helps.","news_type":1,"symbols_score_info":{"AMZN":0.9,"TSLA":0.9,"PFE":0.9}},"isVote":1,"tweetType":1,"viewCount":403,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}